Acnatac® Gel right face — Competitive Intelligence Brief

Acnatac® Gel right face (Acnatac® Gel right face) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

marketed Topical antibiotic combination Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) Dermatology Small molecule

Target snapshot

Acnatac® Gel right face (Acnatac® Gel right face) — GWT-TUD GmbH. Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) to reduce acne-causing bacteria and promote skin cell turnover.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acnatac® Gel right face TARGET	Acnatac® Gel right face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
Duac Gel	Duac Gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Polysporin Ointment	Polysporin Ointment	University of British Columbia	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin) and bacterial cell membrane (polymyxin B)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class